{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:12:48Z","timestamp":1740136368804,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["ref. - RVO (FNBr, 65269705)"],"award-info":[{"award-number":["ref. - RVO (FNBr, 65269705)"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011659","name":"L\u00e9ka\u0159sk\u00e1 fakulta, Masarykova univerzita","doi-asserted-by":"publisher","award":["MUNI \/ A \/ 1325\/2019"],"award-info":[{"award-number":["MUNI \/ A \/ 1325\/2019"]}],"id":[{"id":"10.13039\/501100011659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10072-020-04897-2","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T08:02:51Z","timestamp":1605600171000},"page":"2847-2853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of lymphocytosis and CD4\/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab"],"prefix":"10.1007","volume":"42","author":[{"given":"Jan","family":"Kolcava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Hulova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Rihova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Bednarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-0281","authenticated-orcid":false,"given":"Pavel","family":"Stourac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"4897_CR1","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","volume":"85","author":"H Butzkueven","year":"2014","unstructured":"Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S, on behalf of the TYSABRI Observational Program (TOP) Investigators (2014) Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 85:1190\u20131197. https:\/\/doi.org\/10.1136\/jnnp-2013-306936","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4897_CR2","doi-asserted-by":"publisher","unstructured":"Puthenparampil M, Cazzola C, Zywicki S et al (2018) NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis: therapeutic advances in neurological disorders. https:\/\/doi.org\/10.1177\/1756286418805713","DOI":"10.1177\/1756286418805713"},{"key":"4897_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000109933","volume":"5","author":"B Engelhardt","year":"2008","unstructured":"Engelhardt B, Kappos L (2008) Natalizumab: targeting \u03b14-integrins in multiple sclerosis. NDD 5:16\u201322. https:\/\/doi.org\/10.1159\/000109933","journal-title":"NDD"},{"key":"4897_CR4","doi-asserted-by":"publisher","unstructured":"Camponeschi A, Gerasimcik N, Wang Y, Fredriksson T, Chen D, Farroni C, Thorarinsdottir K, Sj\u00f6kvist Ottsj\u00f6 L, Aranburu A, Cardell S, Carsetti R, Gjertsson I, M\u00e5rtensson IL, Grimsholm O (2019) Dissecting integrin expression and function on memory B cells in mice and humans in autoimmunity. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.00534","DOI":"10.3389\/fimmu.2019.00534"},{"key":"4897_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.humimm.2009.09.360","volume":"71","author":"TK Kim","year":"2010","unstructured":"Kim TK, Billard MJ, Wieder ED, McIntyre BW, Komanduri KV (2010) Co-engagement of \u03b14\u03b21 integrin (VLA-4) and CD4 or CD8 is necessary to induce maximal Erk1\/2 phosphorylation and cytokine production in human T cells. Hum Immunol 71:23\u201328. https:\/\/doi.org\/10.1016\/j.humimm.2009.09.360","journal-title":"Hum Immunol"},{"key":"4897_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1177\/1352458510392263","volume":"17","author":"G Frisullo","year":"2011","unstructured":"Frisullo G, Iorio R, Plantone D, Marti A, Nociti V, Patanella AK, Batocchi AP (2011) CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler 17:556\u2013566. https:\/\/doi.org\/10.1177\/1352458510392263","journal-title":"Mult Scler"},{"key":"4897_CR7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1517\/14712590903055011","volume":"9","author":"F Neumann","year":"2009","unstructured":"Neumann F, Zohren F, Haas R (2009) The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 9:1099\u20131106. https:\/\/doi.org\/10.1517\/14712590903055011","journal-title":"Expert Opin Biol Ther"},{"key":"4897_CR8","doi-asserted-by":"publisher","unstructured":"Signoriello E, Lanzillo R, Morra VB et al (2015) Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458515604381","DOI":"10.1177\/1352458515604381"},{"key":"4897_CR9","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880. https:\/\/doi.org\/10.1056\/NEJMoa1107829","journal-title":"N Engl J Med"},{"key":"4897_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1128\/CMR.05031-11","volume":"25","author":"MW Ferenczy","year":"2012","unstructured":"Ferenczy MW, Marshall LJ, Nelson CDS, Atwood WJ, Nath A, Khalili K, Major EO (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471\u2013506. https:\/\/doi.org\/10.1128\/CMR.05031-11","journal-title":"Clin Microbiol Rev"},{"key":"4897_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jnnp-2015-311100","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87:117\u2013125. https:\/\/doi.org\/10.1136\/jnnp-2015-311100","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4897_CR12","doi-asserted-by":"publisher","unstructured":"Olsson T, Achiron A, Alfredsson L et al (2013) Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458513477925","DOI":"10.1177\/1352458513477925"},{"key":"4897_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425\u2013437. https:\/\/doi.org\/10.1016\/S1474-4422(10)70040-5","journal-title":"Lancet Neurol"},{"key":"4897_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295\u2013303. https:\/\/doi.org\/10.1002\/ana.22128","journal-title":"Ann Neurol"},{"key":"4897_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jns.2016.03.050","volume":"365","author":"Y Aladro","year":"2016","unstructured":"Aladro Y, Terrero R, Cerezo M, Ginestal R, Ayuso L, Meca-Lallana V, Mill\u00e1n J, Borrego L, Martinez-Gin\u00e9s M, Rubio L, de Andr\u00e9s C, Miralles A, Guijarro C, Rodr\u00edguez-Garc\u00eda E, Garc\u00eda-Dominguez JM, Mu\u00f1oz-Fern\u00e1ndez C, L\u00f3pez de Silanes C, G\u00f3mez M, Thuissard I, Cerd\u00e1n M, Palm\u00ed I, D\u00edaz-Garz\u00f3n LF, Meca-Lallana J (2016) Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain. J Neurol Sci 365:16\u201321. https:\/\/doi.org\/10.1016\/j.jns.2016.03.050","journal-title":"J Neurol Sci"},{"key":"4897_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/ana.22606","volume":"70","author":"C Bozic","year":"2011","unstructured":"Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, Sandrock A, Bloomgren G (2011) Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70:742\u2013750. https:\/\/doi.org\/10.1002\/ana.22606","journal-title":"Ann Neurol"},{"key":"4897_CR17","doi-asserted-by":"publisher","first-page":"e0174005","DOI":"10.1371\/journal.pone.0174005","volume":"12","author":"H Hegen","year":"2017","unstructured":"Hegen H, Auer M, Bsteh G, di Pauli F, Plavina T, Walde J, Deisenhammer F, Berger T (2017) Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study. PLoS One 12:e0174005. https:\/\/doi.org\/10.1371\/journal.pone.0174005","journal-title":"PLoS One"},{"key":"4897_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/ane.12475","volume":"133","author":"M Kolasa","year":"2016","unstructured":"Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I (2016) Anti-JC virus seroprevalence in a Finnish MS cohort. Acta Neurol Scand 133:391\u2013397. https:\/\/doi.org\/10.1111\/ane.12475","journal-title":"Acta Neurol Scand"},{"key":"4897_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.msard.2019.02.019","volume":"30","author":"J Kolcava","year":"2019","unstructured":"Kolcava J, Hulova M, Benesova Y, Bednarik J, Stourac P (2019) The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings. Mult Scler Relat Disord 30:187\u2013191. https:\/\/doi.org\/10.1016\/j.msard.2019.02.019","journal-title":"Mult Scler Relat Disord"},{"key":"4897_CR20","doi-asserted-by":"publisher","unstructured":"Outteryck O, Z\u00e9phir H, Salleron J et al (2013) JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458513505353","DOI":"10.1177\/1352458513505353"},{"key":"4897_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/ene.12988","volume":"23","author":"A Vennegoor","year":"2016","unstructured":"Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JLAN, Uitdehaag BMJ, Killestein J (2016) High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol 23:1079\u20131085. https:\/\/doi.org\/10.1111\/ene.12988","journal-title":"Eur J Neurol"},{"key":"4897_CR22","doi-asserted-by":"publisher","first-page":"e0160277","DOI":"10.1371\/journal.pone.0160277","volume":"11","author":"M Iannetta","year":"2016","unstructured":"Iannetta M, Zingaropoli MA, Bellizzi A, Morreale M, Pontecorvo S, D\u2019Abramo A, Oliva A, Anzivino E, Lo Menzo S, D\u2019Agostino C, Mastroianni CM, Millefiorini E, Pietropaolo V, Francia A, Vullo V, Ciardi MR (2016) Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation. PLoS One 11:e0160277. https:\/\/doi.org\/10.1371\/journal.pone.0160277","journal-title":"PLoS One"},{"key":"4897_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/cei.12261","volume":"176","author":"T Koudriavtseva","year":"2014","unstructured":"Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D'Agosto G, Cordiali-Fei P (2014) Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. Clin Exp Immunol 176:320\u2013326. https:\/\/doi.org\/10.1111\/cei.12261","journal-title":"Clin Exp Immunol"},{"key":"4897_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ana.20858","volume":"59","author":"O St\u00fcve","year":"2006","unstructured":"St\u00fcve O, Marra CM, Jerome KR et al (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743\u2013747. https:\/\/doi.org\/10.1002\/ana.20858","journal-title":"Ann Neurol"},{"key":"4897_CR25","doi-asserted-by":"publisher","unstructured":"Warnke C, Stettner M, Lehmensiek V et al (2014) Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458514556296","DOI":"10.1177\/1352458514556296"},{"key":"4897_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintor\u00e9 M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"4897_CR27","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1212\/NXI.0000000000000029","volume":"1","author":"I Kister","year":"2014","unstructured":"Kister I, Kuesters G, Chamot E, Omari M, Dontas K, Yarussi M, Subramanyam M, Herbert J (2014) IV immunoglobulin confounds JC virus antibody serostatus determination. Neurol Neuroimmunol Neuroinflamm 1:e29. https:\/\/doi.org\/10.1212\/NXI.0000000000000029","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4897_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M (2013) A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57:141\u2013146. https:\/\/doi.org\/10.1016\/j.jcv.2013.02.002","journal-title":"J Clin Virol"},{"key":"4897_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jneuroim.2017.05.006","volume":"309","author":"A Carotenuto","year":"2017","unstructured":"Carotenuto A, Scalia G, Ausiello F, Moccia M, Russo CV, Sacc\u00e0 F, de Rosa A, Criscuolo C, del Vecchio L, Brescia Morra V, Lanzillo R (2017) CD4\/CD8 ratio during natalizumab treatment in multiple sclerosis patients. J Neuroimmunol 309:47\u201350. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.006","journal-title":"J Neuroimmunol"},{"issue":"Suppl 3","key":"4897_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10072-010-0344-z","volume":"31","author":"F Sangalli","year":"2011","unstructured":"Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M, Vitello G, Grimaldi LME, Ghezzi A, Martinelli V, Comi G (2011) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31(Suppl 3):299\u2013302. https:\/\/doi.org\/10.1007\/s10072-010-0344-z","journal-title":"Neurol Sci"},{"key":"4897_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1352458512448106","volume":"19","author":"S Rossi","year":"2013","unstructured":"Rossi S, Motta C, Studer V, Monteleone F, de Chiara V, Buttari F, Barbieri F, Bernardi G, Battistini L, Cutter G, St\u00fcve O, Salvetti M, Centonze D (2013) A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Mult Scler 19:59\u201368. https:\/\/doi.org\/10.1177\/1352458512448106","journal-title":"Mult Scler"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04897-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T08:12:25Z","timestamp":1625645545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04897-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4897"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04897-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research was approved by the local ethics committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}